Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective, 2026, Blakney et al.

[SNT Gatchaman]

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective

Spoiler: Authors

Anna K Blakney; Karina A Top; Benjamin J Cowling; Heidi J Larson; Robin J Shattock; Manish Sadarangani

mRNA vaccines represent a transformative advance in vaccinology, combining rapid development timelines, scalable manufacturing, and strong immunogenicity with a favourable safety profile. Global deployment of mRNA vaccines during the COVID-19 pandemic provided an unprecedented real-world evaluation of this platform, with billions of doses administered across diverse populations.

In this Review, we critically examine the safety and efficacy of mRNA vaccines from mechanistic, preclinical, clinical, and public health perspectives. We outline the biological basis of mRNA vaccines, including their transient cytoplasmic expression, lack of genomic integration, and rapid clearance, distinguishing them clearly from other gene therapies. We synthesise evidence on vaccine components, manufacturing quality controls, and regulatory standards that underpin safety, alongside data from randomised trials, post-authorisation surveillance, and active pharmacovigilance systems.

We also review real-world effectiveness across age groups, pregnancy, and populations that are immunocompromised, along with the effects on transmission. Last, we address public perception and vaccine confidence, and discuss implications for next-generation mRNA vaccines, including strategies to reduce reactogenicity, improve breadth and durability of immunity, enhance global access, and support sustainable public trust.

Together, the accumulated evidence affirms mRNA vaccines as a safe, effective, and adaptable platform with enduring relevance for future infectious disease prevention and public health preparedness, and for the treatment of cancer and autoimmunity.

Web | DOI | PDF | The Lancet | Paywall

 

[SNT Gatchaman]

The cumulative evidence from mechanistic studies, randomised trials, and extensive post-authorisation surveillance shows that mRNA vaccines are both safe and highly effective. mRNA vaccine mechanism of action and transient cytoplasmic mRNA translation without genomic integration, coupled with rapid clearance of both RNA and lipid components, underpins a favourable safety profile that is distinct from gene therapy and persistent viral vector platforms. Across billions of administered doses, serious adverse events have been rare, well characterised, and consistently outweighed by the substantial protection conferred against severe disease, hospitalisation, and death. Effectiveness has been shown across age groups, in pregnancy, and in populations that are immunocompromised, establishing mRNA vaccines as a clinically validated and adaptable platform.